Phase 2 study of the anti-angiogenesis agent AG-013736 as second- or later-line treatment in patients with advanced non-small cell lung cancer.
Phase of Trial: Phase II
Latest Information Update: 25 Jun 2012
At a glance
- Drugs Axitinib (Primary)
- Indications Cancer metastases; Non-small cell lung cancer
- Focus Therapeutic Use
- 25 Feb 2012 Additional location (Germany) added as reported by ClinicalTrials.gov.
- 11 Oct 2007 The expected completion date for this trial is now 1 Jul 2007.
- 04 Oct 2007 Status change from in progress to completed.